Insulin resistance and compensatory hyperinsulinemia, both consequences of obesity and lipotoxicity, are well-known risk factors for the development of atherosclerosis ([@B1]). Recent findings from animal models outlined that a combination of insulin resistance and hyperinsulinemia promote changes in the liver's ability to regulate lipoprotein release, which leads to atherogenic dyslipidemia ([@B2]). Insulin resistance is causative of unbalanced regulation of transcription factors FoxO1 and FoxA2, which act on the control of VLDL synthesis, whereas hyperinsulinemia may favor lipogenesis through upregulation of transcription factor SREBP2c activity ([@B3]). However, atherosclerosis is also an inflammatory process, and how insulin resistance and hyperinsulinemia act in the regulation of innate and adaptive immunity is still debated ([@B4]). Data from experimental models have yielded contradictory results. In fact, whereas liver-specific insulin resistance promotes atherosclerosis ([@B5]), genetic models of insulin resistance in monocytes, the master regulator of atherosclerotic plaque progression, were found to either promote or prevent lipid accumulation in aortas depending on the strain of mice used ([@B6],[@B7]). Nevertheless, the activation of monocytes and their propensity to differentiate into macrophages contributes to insulin resistance in different tissues as well as atherosclerosis ([@B8]).

In humans, it is unclear if insulin resistance at the monocyte level is associated with insulin resistance and atherosclerosis in vivo. Here we have used the offspring of patients with type 2 diabetes, a well-characterized model to study how metabolic factors influence vascular homeostasis ([@B9],[@B10]), to investigate whether a reduction in components of the insulin signal transduction pathways, such as the insulin receptor (InsR) or InsR substrate 1 or 2 (IRS1 or IRS2), or genetic modifiers of insulin action, such as the TIMP3/ADAM17 (tissue inhibitor of metalloproteinase 3/A disintegrin and metalloprotease domain 17) pathway, is associated with evidence of atherosclerosis.

RESEARCH DESIGN AND METHODS {#s5}
===========================

The study was approved by the local ethics committee and the reported investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000. An informed written consent was obtained from all participants. A total of 41 unrelated, first-degree relatives (FDRs) of type 2 diabetic patients were enrolled at the Hospital Policlinico Tor Vergata. Inclusion criteria were the eldest offspring in each family with only one parent affected by type 2 diabetes, absence of diabetes (fasting plasma glucose \<7.0 mmol/L and/or 2-h post oral glucose tolerance test \<11.1 mmol/L), and absence of diseases able to modify glucose metabolism. The clinical characteristics of the parents are included in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1). On the first day, after 12 h of fasting, FDRs underwent anthropometrical evaluation, including BMI and waist circumference, measurements of clinic blood pressure after 5 min of quiet rest, a 75-g oral glucose tolerance test, measurements of the intima-media thickness (IMT) of the common carotid artery, and evaluation of the endothelial function as previously described ([@B8],[@B9]). On the second day, after a 12-h overnight fast, subjects underwent a euglycemic hyperinsulinemic clamp study as previously described ([@B9]).

Enzyme-linked immunosorbent assay. {#s6}
----------------------------------

Serum samples were analyzed by a sandwich enzyme-linked immunosorbent assay (ELISA) method using anti-mouse antibodies for human soluble tumor necrosis factor (TNF) receptor 1, soluble interleukin 6 (IL-6) receptor, soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble chemokine (C-X-C motif) ligand 16, and sCXC3L1 (all from R&D Systems, Minneapolis, MN) according to manufacturer's instructions.

Monocyte isolation for RNA extraction and real-time quantitative RT-PCR analysis. {#s7}
---------------------------------------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) were isolated from 40 mL of peripheral blood of FDRs using Ficoll-Plaque Plus (GE Healthcare, Piscataway, NJ) as indicated by the manufacturer. Untouched monocytes were isolated from PBMCs by using an indirect magnetic labeling system (Monocyte Isolation Kit II; Miltenyi Biotec, Auburn, CA). About 2.5--9.7 × 10^6^ monocytes were obtained from 40 mL of peripheral blood. Total RNA was extracted from monocytes with the RNeasy Micro Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Single-strand cDNA was synthesized, according to the Applied Biosystems (Foster City, CA) standard protocol, from 1 μg of total RNA sample using High-Capacity cDNA Archive Kit. Fifty nanograms of cDNA was amplified by real-time PCR RNA expression of TNF-α converting enzyme/*ADAM17*, *ADAM10*, *TNF*-α, *TIMP3*, lectin-like oxidized low-density lipoprotein receptor-1 (*LOX1*), chemokine (C-C motif) receptor 2 (*CCR2*), matrix metalloproteinase 9 (*MMP9*), *InsR*, *IRS1*, *IRS2*, or sirtuin 1 (*SirT1*) (primers available upon request) using an ABI PRISM 7900Ht system (Applied Biosystems) and normalized to 18S rRNA as an endogenous control. Each reaction was carried out in duplicate and analysis was performed by 2^−ΔΔCt^ method.

Protein extraction and pathscan sandwich ELISA assay. {#s8}
-----------------------------------------------------

For protein extraction, monocytes were isolated as described above. Cells (2.5 × 10^6^) were plated in Dulbecco's modified Eagle's medium with 0.2% BSA in the absence of serum for 6 h and then stimulated with insulin (10^−7^ mol/L) for 10 min. At the end of the treatment, in order to assay insulin signaling components, proteins were extracted and analyzed by pathscan sandwich ELISA kits (Cell Signaling, Beverly, MA) according to the manufacturer's instructions. The following pathscan sandwich ELISA kits were used: phospho-InsR (PanTyr) and total InsR; phospho-IRS1 (PanTyr) and total IRS1; phospho-IRS2 (PanTyr) and total IRS2; and phospho-v-akt murine thymoma viral oncogene homolog 1 (AKT1) (Ser473) and total Akt1.

ADAM17 activity assay. {#s9}
----------------------

Protein extracts were used to determine the ADAM17 activity by the SensoLyte 520 ADAM17 activity assay kit (Fluorimetric; AnaSpec, San Jose, CA) according to the manufacturer's instructions.

Statistical analysis. {#s10}
---------------------

The Kolmogorov-Smirnov test was used to test the normality of distribution, and nonnormally distributed variables, including all mRNA values, were naturally log transformed. Group differences of continuous variables were compared using Student *t* test or univariate ANOVA test with Bonferroni post-hoc test. Relationships between variables were determined by Pearson correlation coefficient (*r*). Continuous data are expressed as means ± SD. *P* \< 0.05 was considered statistically significant. All analyses were performed using SPSS software program version 13.0 for Windows. Graphs were designed using GraphPad Prism 5.0 for Windows.

RESULTS {#s11}
=======

Correlation between insulin resistance, sublinical atherosclerosis, and gene expression in monocytes from offspring of type 2 diabetic subjects. {#s12}
------------------------------------------------------------------------------------------------------------------------------------------------

By analyzing clinical characteristics and metabolic parameters of FDRs of type 2 diabetes (anthropometric, biochemical, and clinical parameters are shown in [Table 1](#T1){ref-type="table"}), we found that insulin resistance, evaluated as glucose disposal rate (M) during a euglycemic hyperinsulinemic clamp, negatively correlates with IMT (*r* = −0.575; *P* \< 0.0001), and dividing our population into tertiles of insulin resistance assessed by M clamp, we also confirmed that the insulin-resistant tertile has higher IMT values, confirming the validity of this model to study biomarkers linking insulin resistance to atherosclerosis ([@B9],[@B10]) ([Supplementary Fig. 1*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1)). We analyzed the mRNA expression levels of *InsR*, *IRS1*, *IRS2*, and *SirT1*. No correlation was found between levels of InsR, IRS1, and SirT1 expression with clinical and biochemical parameters (data not shown). However, we found in this group of subjects that IRS2 expression correlated with fasting plasma glucose (*r* = −0.34; *P* \< 0.05), insulin resistance assessed by M (*r* = 0.406; *P* \< 0.01), glycated hemoglobin (*r* = −0.36; *P* \< 0.05), HDL cholesterol (*r* = 0.28; *P* \< 0.05), and IMT (*r* = −0.49; *P* \< 0.001) (data not shown). We observed that subjects in the lowest tertiles of expression of *IRS2* in monocytes were significantly more insulin resistant and had the highest IMT level ([Fig. 1*A* and *B*](#F1){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1)); accordingly those with low *IRS2* had increased fasting plasma glucose and HbA~1c~ and reduced levels of HDL cholesterol ([Fig. 1*C*--*E*](#F1){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1)). Next we analyzed the expression of genes relevant for inflammation, such as *TNF*-α, *CCR2*, *LOX1*. Similarly, we did not find correlation between levels of gene expression and clinical and biochemical parameters in this group of subjects. Because mRNA expression could not reflect protein regulation at the membrane and cytoplasmic level, we analyzed the levels of InsR, IRS1, and IRS2 in the lowest versus the highest tertiles of insulin resistance. Our analysis confirmed that in cultured monocytes of insulin-resistant subjects, IRS2 protein and tyrosine phosporylation levels were significantly decreased ([Fig. 2*B*](#F2){ref-type="fig"}), whereas no differences were observed for InsR and IRS1 in both protein expression and phopsphorylation ([Fig. 2*A*](#F2){ref-type="fig"}). Interestingly, whereas Akt1 protein levels were similar in the two groups, Akt serine 473 phosphorylation reflected the reduced IRS2 activation ([Fig. 2*C*](#F2){ref-type="fig"}). Analysis of the subjects with lowest IRS2 protein levels in monocytes confirmed that these were significantly more insulin resistant and had the highest IMT level ([Fig. 2*D*--*H*](#F2){ref-type="fig"}), with results similar to stratification of subjects with IRS2 mRNA levels.

###### 

Distribution of anthropometric and biochemical parameters and monocyte gene expression data according to tertiles of insulin resistance

                                                      All subjects      Insulin resistance   *P* value                           
  --------------------------------------------------- ----------------- -------------------- ----------------- ----------------- --------
  Subjects (*n*)                                      41                13                   14                14                
  Sex (men/women)                                     13/28                                                                      
  Age (years)                                         36.5 ± 10.2       32.7 ± 10.9          35.1 ± 8.8        41.6 ± 9.5        NS
  BMI (kg/m^2^)                                       25.00 ± 4.3       22.1 ± 2.4           25.00 ± 3.4       27.2 ± 3.4        0.001
  Waist (cm)                                          81.9 ± 11.9       73.3 ± 5.0           83.9 ± 11.0       93.0 ± 11.4       0.001
  Hypertension (yes/no)                               6/35                                                                       
  NGT/IGT                                             35/6                                                                       
  Systolic blood pressure (mmHg)                      119.4 ± 13.3      115.9 ± 11.1         120.0 ± 15.5      120.0 ± 19.1      NS
  Diastolic blood pressure (mmHg)                     79.3 ± 8.4        75.4 ± 8.2           81.2 ± 8.0        78.6 ± 9.4        NS
  Total cholesterol (mmol/L)                          4.92 ± 1.07       4.54 ± 1.02          4.86 ± 0.98       5.32 ± 1.12       NS
  HDL cholesterol (mmol/L)                            1.52 ± 0.40       1.79 ± 0.47          1.50 ± 0.34       1.30 ± 0.24       0.005
  LDL cholesterol (mmol/L)                            3.08 ± 1.08       2.57 ± 0.80          2.91 ± 1.01       3.72 ± 1.12       0.01
  Triglycerides (mmol/L)                              1.18 ± 0.77       0.77 ± 0.27          1.07 ± 0.97       1.66 ± 5.09       0.005
  HbA~1c~ (%)                                         5.32 ± 0.27       5.23 ± 0.2           5.34 ± 0.28       5.49 ± 0.28       0.05
  Fasting plasma glucose (mmol/L)                     5.0 ± 0.4         5.0 ± 0.3            4.8 ± 0.4         5.1 ± 0.4         NS
  2 h *p*-l plasma glucose (mmol/L)                   6.6 ± 1.3         5.4 ± 0.9            6.9 ± 1.9         7.0 ± 1.4         0.01
  Fasting plasma insulin (pmol/L)                     60 ± 35           44 ± 22              47 ± 22           89 ± 39           0.001
  2 h *p*-l plasma insulin (pmol/L)                   325 ± 248         212 ± 22             267 ± 104         510 ± 392         0.007
  HOMA IR index                                       2.27 ± 1.42       1.65 ± 0.88          1.66 ± 0.73       3.46 ± 1.62       0.0001
  Glucose disposal index (mg ⋅ kg^−1^ ⋅ min^−1^)      7.88 ± 2.37       10.60 ± 1.41         7.875 ± 0.54      5.49 ± 1.27       0.0001
  Fibrinogen (mg/dL)                                  304.23 ± 81.29    305.92 ± 110.41      311.58 ± 68.01    299.11 ± 70.47    NS
  C-reactive protein (mg/dL)                          4.18 ± 9.14       6.8 ± 14.26          2.34 ± 3.15       2.7 ± 2.29        NS
  Free fatty acids (mmol/L)                           0.47 ± 0.21       0.46 ± 0.17          0.38 ± 0.22       0.58 ± 0.13       NS
  sVCAM-1 (ng/mL)                                     246.01 ± 337.75   145.21 ± 163.53      267.87 ± 225.82   324.93 ± 518.41   NS
  sICAM-1 (ng/mL)                                     166.43 ± 51.97    181.25 ± 66.77       152.76 ± 30.79    164.24 ± 51.31    NS
  sTNF R1 (ng/mL)                                     1.27 ± 0.30       1.28 ± 0.33          1.26 ± 0.13       1.28 ± 0.4        NS
  sIL6 R (ng/mL)                                      26.98 ± 9.27      25.01 ± 8.82         25.57 ± 10.61     30.70 ± 7.86      NS
  Soluble chemokine (C-X-C motif) ligand 16 (ng/mL)   4.11 ± 0.88       4.25 ± 1.05          4.01 ± 0.59       4.08 ± 0.93       NS
  Fractalkine (ng/mL)                                 3.63 ± 8.98       4.94 ± 11.62         5.21 ± 10.38      0.73 ± 1.32       NS
  IMT (mm)                                            0.70 ± 0.09       0.66 ± 0.09          0.67 ± 0.06       0.77 ± 0.11       0.008
  FMD                                                 12.43 ± 6.84      11.22 ± 5.25         13.08 ± 8.99      12.86 ± 6.71      NS
  Log *IR*                                            0.57 ± 0.41       0.71 ± 0.29          0.49 ± 0.46       0.51 ± 0.44       NS
  Log *IRS1*                                          0.22 ± 0.72       0.36 ± 0.47          0.14 ± 0.94       0.17 ± 0.91       NS
  Log *IRS2*                                          0.09 ± 0.29       0.20 ± 0.28          0.09 ± 0.31       0.02 ± 0.30       0.05
  Log *TIMP3*                                         −0.12 ± 0.63      0.14 ± 0.55          −0.22 ± 0.70      −0.26 ± 0.64      0.05
  Log *TACE*                                          −0.11 ± 0.25      −0.06 ± 0.25         −0.17 ± 0.26      −0.10 ± 0.25      NS
  Log *ADAM10*                                        0.48 ± 0.35       0.64 ± 0.32          0.33 ± 0.32       0.56 ± 0.29       NS
  Log *MMP9*                                          −0.07 ± 0.30      −0.07 ± 0.30         −0.15 ± 0.26      −0.08 ± 0.27      NS
  Log *Sirt1*                                         0.56 ± 0.35       0.62 ± 0.29          0.47 ± 0.42       0.62 ± 0.29       NS
  Log *CCR2*                                          −0.06 ± 0.32      0.11 ± 0.29          −0.12 ± 0.36      −0.09 ± 0.32      NS
  Log *TNF*-α                                         −0.52 ± 0.54      −0.57 ± 0.57         −0.94 ± 0.26      −0.26 ± 0.52      NS
  Log *LOX1*                                          −0.36 ± 0.41      −0.34 ± 0.38         −0.44 ± 0.42      −0.32 ± 0.46      NS

Data are percentage or means ± SD, unless otherwise indicated. *P* value is reported for significant differences among groups tested with ANOVA with Bonferroni post-hoc test. NGT, normal glucose tolerance; IGT, impaired glucose tolerance; 2 h *p*-l, 2 h postglucose load; HOMA-IR, homeostasis model assessment of insulin resistance; FMD, flow-mediated dilation; sIL6 R, soluble IL-6 receptor; sTNF R1, soluble TNF receptor 1.

![mRNA expression of *IRS2* in monocytes from FDRs of type 2 diabetic subjects is correlated with in vivo insulin resistance and subclinical atherosclerosis. High log *IRS2* mRNA levels are associated with increased levels of M (*A*), decreased IMT (*B*), decreased fasting plasma glucose levels (*C*), decreased glycated hemoglobin (*D*), and increased HDL cholesterol (*E*). \**P* \< 0.05 for LOW *IRS2* (*n* = 14) compared with HIGH *IRS2* (*n* = 14) by ANOVA with Bonferroni post-hoc test.](3265fig1){#F1}

![InsR and IRS protein levels and phosphorylation status in monocytes from lowest vs. highest insulin resistance tertiles. *A--C*: InsR and IRS1 protein levels and pan-tyrosine are not different in monocytes from insulin-sensitive (*n* = 13) vs. insulin-resistant (*n* = 14) subjects (*A*). IRS2 protein levels and pan-tyrosine phosphorylation are higher in monocytes from insulin-sensitive (*n* = 13) vs. insulin-resistant (*n* = 14) subjects (\**P* \< 0.05, by Student *t* test) (*B*). Akt protein levels and serine 473 phosphorylation are higher in monocytes from insulin-sensitive (*n* = 13) vs. insulin-resistant (*n* = 14) subjects (\**P* \< 0.05, by Student *t* test) (*C*). *D--H*: FDR subjects characterized by lowest IRS2 protein levels in monocytes exhibit significantly increased IMT (*D*), decreased M (*E*), fasting plasma glucose (*F*), HbA~1c~ (*G*), and increased HDL (*H*) (*n* = 14 and *n* = 14 for LOW IRS2 and HIGH IRS2, respectively; \**P* \< 0.05, by Student *t* test). a.u., arbitrary unit.](3265fig2){#F2}

mRNA *TIMP3* expression is reduced in monocytes from insulin-resistant FDRs. {#s13}
----------------------------------------------------------------------------

Recent studies using human specimens and animal models suggested that the regulation of the inflammatory behavior of monocytes is controlled by TIMP3, which restrains the release of the soluble fraction of transmembrane proteins through their ectodomain shedding. This process is regulated by sheddases belonging to the ADAM family of metalloproteases, which generate soluble forms of cytokines, growth factors, and receptors, such as TNF-α, IL-6 receptor, VCAM-1, ICAM-1 and selectins, all involved in the chronic inflammatory process. TIMP3 is the physiological inhibitor of the ADAMs involved in the ectodomain shedding process, such as ADAM17 and ADAM10 ([@B11]).

We analyzed the expression of several genes involved in the membrane ectodomain shedding in monocytes extracted from PBMCs of FDRs, such as *ADAM17*, *ADAM10*, *MMP9*, and *TIMP3*. No correlation was found between gene expression levels and clinical and biochemical parameters. Dividing our population into tertiles of insulin resistance assessed by M clamp, we found that *TIMP3* mRNA levels were significantly reduced in insulin-resistant FDRs ([Table 1](#T1){ref-type="table"} and [Fig. 3*A*](#F3){ref-type="fig"}). Insulin-resistant FDRs carrying lower *TIMP3* expression were characterized by significantly increased ADAM17 activity ([Fig. 3*B*](#F3){ref-type="fig"}). *TIMP3* mRNA levels were negatively correlated with IMT (*r* = −0.43; *P* \< 0.05) ([Fig. 3*C*](#F3){ref-type="fig"}). Further analysis revealed that in monocytes, there is a correlation between *IRS2* and *TIMP3* expression ([Fig. 3*D*](#F3){ref-type="fig"}), with subjects in the lowest tertile of *IRS2* expression having reduced *TIMP3* levels ([Fig. 3*E*](#F3){ref-type="fig"}) and increased ectodomain shedding activity, as suggested by increased circulating soluble IL-6 receptor and sVCAM-1 ([Fig. 3*F*](#F3){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1)).

![TIMP3 and ADAM17 pathway in monocytes from FDRs. *A*: TIMP3 expression is higher in insulin-sensitive compared with insulin-resistant FDR subjects (\**P* \< 0.05 for LOW M \[*n* = 14\] compared with HIGH M \[*n* = 13\] by ANOVA with Bonferroni multiple comparison tests). *B*: ADAM17 activity is significantly higher in monocyte extracts from insulin-resistant (black bar; *n* = 14) compared with insulin-sensitive (white bar; *n* = 13) FDR subjects (\**P* \< 0.05 by Student *t* test). *C*: mRNA expression of TIMP3 in monocytes from FDRs of type 2 diabetic subjects is negatively correlated with subclinical atherosclerosis. *D*: Expression of TIMP3 in monocytes from FDRs of type 2 diabetic subjects is positively correlated with IRS2 mRNA levels. *E*: Expression of TIMP3 in monocytes from FDRs of type 2 diabetic subjects is reduced according to IRS2 mRNA expressed in tertiles. *F*: Soluble IL-6 receptor (rec), a marker of increased ectodomain shedding, is significantly higher in subjects with lowest IRS2 mRNA expression levels. \**P* \< 0.05 for LOW IRS2 (*n* = 14) compared with HIGH IRS2 (*n* = 14) by Student *t* test. a.u., arbitrary unit.](3265fig3){#F3}

DISCUSSION {#s14}
==========

The contradictory results from monocyte-specific InsR knockouts do not provide definitive evidence for a positive or negative role of myeloid insulin resistance in the pathogenesis of diabetes and atherosclerosis in humans ([@B4]--[@B7],[@B12]).

Here, we observe no correlation between insulin resistance, subclinical atherosclerosis, and InsR in monocytes from human subjects. In contrast, expression of IRS2, the major transduction element of InsR tyrosine kinase in myeloid cells ([@B13],[@B14]), was correlated to both systemic insulin resistance and subclinical atherosclerosis. Overall, in subjects at risk for diabetes, those with insulin resistance and increased IMT carry lower expression of IRS2 in circulating monocytes, suggesting that myeloid-specific insulin resistance at the molecular level facilitates the development of atherosclerosis and diabetes. The reduced *IRS2* expression might be explained by the exposure to different insulin levels, since relative hyperinsulinemia and insulin resistance are known to affect *IRS2* expression through AkT/FoxO1 activation ([@B15]).

The inflammatory behavior of circulating monocytes is dependent on several checkpoints ([@B16]). One extracellular factor regulating innate response is TIMP3, through its ability to restrain release of cytokines and chemokines from the plasma membrane ([@B11],[@B17]).

Monocytes from subjects characterized by increased insulin resistance and atherosclerosis exhibit reduced mRNA *TIMP3* levels. We previously established that TIMP3 is a genetic modifier for insulin resistance in mice; it is reduced in atherosclerotic plaques of subjects with type 2 diabetes, as a result of altered SirT1 activity on vascular smooth muscle cells and monocytes ([@B18],[@B19]). Hyperinsulinemia (a compensatory response to peripheral insulin resistance) is known to increase ADAM10 and ADAM17 activity, the inflammatory metalloproteases that are restrained by TIMP3, causing increased release of transmembrane proteins as soluble factors ([@B20],[@B21]). Among transmembrane proteins with chemokine activity, we found that in offspring of patients with type 2 diabetes, soluble IL-6 receptor and sVCAM-1 were positively correlated with insulin resistance and markers of atherogenic dyslipidemia, suggesting a role for these chemokines in the early phases of metabolic inflammation.

In conclusion, in monocyte cells from human subjects with increased risk for diabetes and atherosclerosis, we found that gene expression and protein activity of IRS2, but not InsR, negatively correlates with insulin resistance and atherosclerosis. Moreover, TIMP3, a natural checkpoint for inflammation, is reduced along with insulin resistance. Our data suggest that the reduction of TIMP3 may increase the release of inflammatory soluble factors generated through the ectodomain shedding activity of metalloproteases such as ADAM17, a process starting at preclinical levels with release of soluble IL-6 receptor. Intriguingly, data in experimental models suggested that low TIMP3 expression defines a subpopulation of highly invasive foam-cell macrophages with increased proliferation and apoptosis, all properties expected to destabilize atherosclerotic plaques ([@B22]).

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0162/-/DC1>.
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